TY - JOUR AU - Coindre, J. M. AU - Terrier, P. AU - Bui, N. B. AU - Bonichon, F. AU - Collin, F. AU - Doussal, V. PY - 1996 DA - 1996// TI - Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group JO - J Clin Oncol VL - 14 UR - https://doi.org/10.1200/JCO.1996.14.3.869 DO - 10.1200/JCO.1996.14.3.869 ID - Coindre1996 ER - TY - JOUR AU - Italiano, A. AU - Mathoulin-Pelissier, S. AU - Cesne, A. L. AU - Terrier, P. AU - Bonvalot, S. AU - Collin, F. PY - 2011 DA - 2011// TI - Trends in survival for patients with metastatic soft-tissue sarcoma JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25538 DO - 10.1002/cncr.25538 ID - Italiano2011 ER - TY - JOUR AU - Demetri, G. D. AU - Mehren, M. AU - Jones, R. L. AU - Hensley, M. L. AU - Schuetze, S. M. AU - Staddon, A. PY - 2016 DA - 2016// TI - Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.4734 DO - 10.1200/JCO.2015.62.4734 ID - Demetri2016 ER - TY - JOUR AU - Kawai, A. AU - Araki, N. AU - Sugiura, H. AU - Ueda, T. AU - Yonemoto, T. AU - Takahashi, M. PY - 2015 DA - 2015// TI - Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70098-7 DO - 10.1016/S1470-2045(15)70098-7 ID - Kawai2015 ER - TY - JOUR AU - Garcia-Carbonero, R. AU - Supko, J. G. AU - Manola, J. AU - Seiden, M. V. AU - Harmon, D. AU - Ryan, D. P. PY - 2004 DA - 2004// TI - Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.02.098 DO - 10.1200/JCO.2004.02.098 ID - Garcia-Carbonero2004 ER - TY - JOUR AU - Cesne, A. AU - Blay, J. Y. AU - Judson, I. AU - Oosterom, A. AU - Verweij, J. AU - Radford, J. PY - 2005 DA - 2005// TI - Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.180 DO - 10.1200/JCO.2005.01.180 ID - Cesne2005 ER - TY - JOUR AU - Yovine, A. AU - Riofrio, M. AU - Blay, J. Y. AU - Brain, E. AU - Alexandre, J. AU - Kahatt, C. PY - 2004 DA - 2004// TI - Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.210 DO - 10.1200/JCO.2004.05.210 ID - Yovine2004 ER - TY - JOUR AU - Damia, G. AU - Silvestri, S. AU - Carrassa, L. AU - Filiberti, L. AU - Faircloth, G. T. AU - Liberi, G. PY - 2001 DA - 2001// TI - Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways JO - Int J Cancer VL - 92 UR - https://doi.org/10.1002/ijc.1221 DO - 10.1002/ijc.1221 ID - Damia2001 ER - TY - JOUR AU - Erba, E. AU - Bergamaschi, D. AU - Bassano, L. AU - Damia, G. AU - Ronzoni, S. AU - Faircloth, G. T. PY - 2001 DA - 2001// TI - Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action JO - Eur J Cancer VL - 37 UR - https://doi.org/10.1016/S0959-8049(00)00357-9 DO - 10.1016/S0959-8049(00)00357-9 ID - Erba2001 ER - TY - JOUR AU - Herrero, A. B. AU - Martín-Castellanos, C. AU - Marco, E. AU - Gago, F. AU - Moreno, S. PY - 2006 DA - 2006// TI - Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-0179 DO - 10.1158/0008-5472.CAN-06-0179 ID - Herrero2006 ER - TY - JOUR AU - Soares, D. G. AU - Escargueil, A. E. AU - Poindessous, V. AU - Sarasin, A. AU - Gramont, A. AU - Bonatto, D. PY - 2007 DA - 2007// TI - Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0609877104 DO - 10.1073/pnas.0609877104 ID - Soares2007 ER - TY - JOUR AU - Takebayashi, Y. AU - Pourquier, P. AU - Zimonjic, D. B. AU - Nakayama, K. AU - Emmert, S. AU - Ueda, T. PY - 2001 DA - 2001// TI - Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair JO - Nat Med VL - 7 UR - https://doi.org/10.1038/91008 DO - 10.1038/91008 ID - Takebayashi2001 ER - TY - JOUR AU - Hoeijmakers, J. H. J. PY - 2009 DA - 2009// TI - DNA damage, aging, and cancer JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMra0804615 DO - 10.1056/NEJMra0804615 ID - Hoeijmakers2009 ER - TY - JOUR AU - Moynahan, M. E. AU - Jasin, M. PY - 2010 DA - 2010// TI - Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis JO - Nat Rev Mol Cell Biol VL - 11 UR - https://doi.org/10.1038/nrm2851 DO - 10.1038/nrm2851 ID - Moynahan2010 ER - TY - JOUR AU - D’Incalci, M. AU - Erba, E. AU - Damia, G. AU - Galliera, E. AU - Carrassa, L. AU - Marchini, S. PY - 2002 DA - 2002// TI - Unique features of the mode of action of ET-743 JO - Oncologist VL - 7 UR - https://doi.org/10.1634/theoncologist.7-3-210 DO - 10.1634/theoncologist.7-3-210 ID - D’Incalci2002 ER - TY - JOUR AU - Stevens, E. V. AU - Nishizuka, S. AU - Antony, S. AU - Reimers, M. AU - Varma, S. AU - Young, L. PY - 2008 DA - 2008// TI - Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-07-0192 DO - 10.1158/1535-7163.MCT-07-0192 ID - Stevens2008 ER - TY - JOUR AU - Huen, M. S. AU - Sy, S. M. AU - Chen, J. PY - 2009 DA - 2009// TI - BRCA1 and its toolbox for the maintenance of genome integrity JO - Nat Rev Mol Cell Biol VL - 11 UR - https://doi.org/10.1038/nrm2831 DO - 10.1038/nrm2831 ID - Huen2009 ER - TY - JOUR AU - Martínez, N. AU - Sánchez-Beato, M. AU - Carnero, A. AU - Moneo, V. AU - Tercero, J. C. AU - Fernández, I. PY - 2005 DA - 2005// TI - Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients JO - Mol Cancer Ther VL - 4 UR - https://doi.org/10.1158/1535-7163.MCT-04-0316 DO - 10.1158/1535-7163.MCT-04-0316 ID - Martínez2005 ER - TY - JOUR AU - Laroche-Clary, A. AU - Chaire, V. AU - Morvan, V. AU - Neuville, A. AU - Bertucci, F. AU - Salas, S. PY - 2015 DA - 2015// TI - BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients JO - Br J Cancer VL - 112 UR - https://doi.org/10.1038/bjc.2014.624 DO - 10.1038/bjc.2014.624 ID - Laroche-Clary2015 ER - TY - JOUR AU - Italiano, A. AU - Laurand, A. AU - Laroche, A. AU - Casali, P. AU - Sanfilippo, R. AU - Cesne, A. PY - 2011 DA - 2011// TI - ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25925 DO - 10.1002/cncr.25925 ID - Italiano2011 ER - TY - JOUR AU - Javle, M. AU - Curtin, N. J. PY - 2011 DA - 2011// TI - The role of PARP in DNA repair and its therapeutic exploitation JO - Br J Cancer VL - 105 UR - https://doi.org/10.1038/bjc.2011.382 DO - 10.1038/bjc.2011.382 ID - Javle2011 ER - TY - JOUR AU - Avilla-Arroyo, S. AU - Nunez, G. S. AU - Garcia-fernandez, L. F. AU - Galmaricini, C. M. PY - 2015 DA - 2015// TI - Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines JO - J Breast Cancer VL - 18 UR - https://doi.org/10.4048/jbc.2015.18.4.329 DO - 10.4048/jbc.2015.18.4.329 ID - Avilla-Arroyo2015 ER - TY - JOUR AU - Plummer, R. AU - Jones, C. AU - Middleton, M. AU - Wilson, R. AU - Evans, J. AU - Olsen, A. PY - 2008 DA - 2008// TI - Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-1223 DO - 10.1158/1078-0432.CCR-08-1223 ID - Plummer2008 ER - TY - JOUR AU - Chou, T. C. AU - Talalay, P. PY - 1984 DA - 1984// TI - Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors JO - Adv Enzyme Regul VL - 22 UR - https://doi.org/10.1016/0065-2571(84)90007-4 DO - 10.1016/0065-2571(84)90007-4 ID - Chou1984 ER - TY - JOUR AU - Xing, D. AU - Scangas, G. AU - Nitta, M. AU - He, L. AU - Xu, X. AU - Ioffe, Y. J. PY - 2009 DA - 2009// TI - A role for BRCA1 in uterine leiomyosarcoma JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-2543 DO - 10.1158/0008-5472.CAN-09-2543 ID - Xing2009 ER - TY - JOUR AU - Schöffski, P. AU - Taron, M. AU - Jimeno, J. AU - Grosso, F. AU - Sanfilipio, R. AU - Casali, P. G. PY - 2011 DA - 2011// TI - Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study JO - Eur J Cancer VL - 47 UR - https://doi.org/10.1016/j.ejca.2011.01.016 DO - 10.1016/j.ejca.2011.01.016 ID - Schöffski2011 ER - TY - JOUR AU - Turner, N. AU - Tutt, A. AU - Ashworth, A. PY - 2004 DA - 2004// TI - Hallmarks of ‘BRCAness’ in sporadic cancers JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1457 DO - 10.1038/nrc1457 ID - Turner2004 ER - TY - JOUR AU - McCabe, N. AU - Turner, N. C. AU - Lord, C. J. AU - Kluzek, K. AU - Bialkowska, A. AU - Swift, S. PY - 2006 DA - 2006// TI - Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-0140 DO - 10.1158/0008-5472.CAN-06-0140 ID - McCabe2006 ER - TY - JOUR AU - Williamson, C. T. AU - Muzik, H. AU - Turhan, A. G. AU - Zamò, A. AU - O’Connor, M. J. AU - Bebb, D. G. PY - 2010 DA - 2010// TI - ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-0872 DO - 10.1158/1535-7163.MCT-09-0872 ID - Williamson2010 ER - TY - JOUR AU - Ul-Hassan, A. AU - Sisley, K. AU - Hughes, D. AU - Hammond, D. W. AU - Robinson, M. H. AU - Reed, M. W. PY - 2009 DA - 2009// TI - Common genetic changes in leiomyosarcoma and gastrointestinal stromal tumour: implication for ataxia telangiectasia mutated involvement JO - Int J Exp Pathol VL - 90 UR - https://doi.org/10.1111/j.1365-2613.2009.00680.x DO - 10.1111/j.1365-2613.2009.00680.x ID - Ul-Hassan2009 ER - TY - JOUR AU - Zhang, P. AU - Bhakta, K. S. AU - Puri, P. L. AU - Newbury, R. O. AU - Feramisco, J. R. AU - Wang, J. Y. PY - 2003 DA - 2003// TI - Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma JO - Cancer Biol Ther VL - 2 ID - Zhang2003 ER - TY - JOUR AU - Mendes-Pereira, A. M. AU - Martin, S. A. AU - Brough, R. AU - McCarthy, A. AU - Taylor, J. R. AU - Kim, J. S. PY - 2009 DA - 2009// TI - Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors JO - EMBO Mol Med VL - 1 UR - https://doi.org/10.1002/emmm.200900041 DO - 10.1002/emmm.200900041 ID - Mendes-Pereira2009 ER - TY - JOUR AU - Hernando, E. AU - Charytonowicz, E. AU - Dudas, M. E. AU - Menendez, S. AU - Matushansky, I. AU - Mills, J. PY - 2007 DA - 2007// TI - The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas JO - Nat Med VL - 13 UR - https://doi.org/10.1038/nm1560 DO - 10.1038/nm1560 ID - Hernando2007 ER - TY - JOUR AU - Puzio-Kuter, A. M. AU - Laddha, S. V. AU - Castillo-Martin, M. AU - Sun, Y. AU - Cordon-Cardo, C. AU - Chan, C. S. PY - 2015 DA - 2015// TI - Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma JO - Cell Death Differ VL - 22 UR - https://doi.org/10.1038/cdd.2015.27 DO - 10.1038/cdd.2015.27 ID - Puzio-Kuter2015 ER - TY - JOUR AU - Tentori, L. AU - Graziani, G. PY - 2005 DA - 2005// TI - Chemopotentiation by PARP inhibitors in cancer therapy JO - Pharmacol Res VL - 52 UR - https://doi.org/10.1016/j.phrs.2005.02.010 DO - 10.1016/j.phrs.2005.02.010 ID - Tentori2005 ER - TY - JOUR AU - Tentori, L. AU - Leonetti, C. AU - Scarsella, M. AU - Muzi, A. AU - Mazzon, E. AU - Vergati, M. PY - 2006 DA - 2006// TI - Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma JO - FASEB J VL - 20 UR - https://doi.org/10.1096/fj.06-5916fje DO - 10.1096/fj.06-5916fje ID - Tentori2006 ER - TY - JOUR AU - Bernges, F. AU - Zeller, W. J. PY - 1996 DA - 1996// TI - Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines—with special reference to cisplatin JO - J Cancer Res Clin Oncol VL - 122 UR - https://doi.org/10.1007/BF01209029 DO - 10.1007/BF01209029 ID - Bernges1996 ER - TY - JOUR AU - Donawho, C. K. AU - Luo, Y. AU - Luo, Y. AU - Penning, T. D. AU - Bauch, J. L. AU - Bouska, J. J. PY - 2007 DA - 2007// TI - ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-3039 DO - 10.1158/1078-0432.CCR-06-3039 ID - Donawho2007 ER - TY - STD TI - Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget. 2015;6:18875–90. doi: 10.18632/oncotarget.4303. ID - ref39 ER - TY - STD TI - Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. Cancer Invest. 2015;33(9):440–50. doi:10.3109/07357907.2015.1064534. ID - ref40 ER -